SG Americas Securities LLC Has $647,000 Position in Cerus Co. (NASDAQ:CERS)

SG Americas Securities LLC grew its position in Cerus Co. (NASDAQ:CERSGet Rating) by 16.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 179,775 shares of the biotechnology company’s stock after purchasing an additional 24,909 shares during the period. SG Americas Securities LLC’s holdings in Cerus were worth $647,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in CERS. Vanguard Group Inc. lifted its position in Cerus by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 9,042,411 shares of the biotechnology company’s stock worth $49,643,000 after buying an additional 219,535 shares in the last quarter. Wasatch Advisors Inc. lifted its position in Cerus by 2.9% during the 1st quarter. Wasatch Advisors Inc. now owns 8,425,608 shares of the biotechnology company’s stock worth $46,257,000 after buying an additional 236,787 shares in the last quarter. State Street Corp raised its holdings in Cerus by 4.3% during the 1st quarter. State Street Corp now owns 4,634,744 shares of the biotechnology company’s stock worth $25,445,000 after purchasing an additional 193,036 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in Cerus by 927.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 2,986,492 shares of the biotechnology company’s stock worth $15,799,000 after purchasing an additional 2,695,901 shares during the last quarter. Finally, Silverarc Capital Management LLC raised its holdings in Cerus by 49.7% during the 2nd quarter. Silverarc Capital Management LLC now owns 2,093,861 shares of the biotechnology company’s stock worth $11,077,000 after purchasing an additional 695,461 shares during the last quarter. Institutional investors and hedge funds own 82.47% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on CERS. BTIG Research cut Cerus from a “buy” rating to a “neutral” rating in a report on Friday. StockNews.com started coverage on Cerus in a report on Wednesday, October 12th. They set a “hold” rating for the company. Stephens cut Cerus from an “overweight” rating to an “equal weight” rating and set a $3.75 price target for the company. in a research note on Tuesday, January 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Cerus in a research note on Monday, December 5th.

Cerus Price Performance

NASDAQ CERS opened at $3.12 on Friday. The business has a 50 day simple moving average of $3.70 and a 200 day simple moving average of $4.15. Cerus Co. has a 52-week low of $2.53 and a 52-week high of $6.00. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.44 and a current ratio of 1.73. The stock has a market cap of $553.55 million, a price-to-earnings ratio of -14.18 and a beta of 1.09.

Cerus (NASDAQ:CERSGet Rating) last posted its earnings results on Thursday, November 3rd. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). Cerus had a negative return on equity of 48.32% and a negative net margin of 24.24%. The business had revenue of $39.57 million during the quarter, compared to analysts’ expectations of $39.00 million. Analysts anticipate that Cerus Co. will post -0.21 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Cerus news, Director Daniel N. Swisher, Jr. sold 12,500 shares of the company’s stock in a transaction that occurred on Thursday, November 10th. The stock was sold at an average price of $3.91, for a total transaction of $48,875.00. Following the completion of the transaction, the director now owns 113,808 shares of the company’s stock, valued at approximately $444,989.28. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 7.33% of the stock is owned by company insiders.

About Cerus

(Get Rating)

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Further Reading

Want to see what other hedge funds are holding CERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerus Co. (NASDAQ:CERSGet Rating).

Institutional Ownership by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.